论文部分内容阅读
目的观察普米克令舒和沐舒坦联合雾化吸入治疗慢性阻塞性肺病(COPD)急性加重期的疗效。方法 78例慢性阻塞性肺病(COPD)急性加重期患者随机分为治疗组和对照组。在常规治疗的基础上对照组给予传统药物地塞米松、α一糜蛋白酶、庆大霉素雾化;治疗组给予普米克令舒和沐舒坦联合雾化吸入。结果治疗后气短、呼吸困难症状的改善治疗组超过对照组,两组有显著性差异(P<0.05)。结论普米克令舒和沐舒坦联合雾化吸入具有快速缓解病情、改善症状的作用,在慢性阻塞性肺疾病急性加重期的治疗中具有重要意义。
Objective To observe the curative effect of pulmicort and mucosolvan combined with inhalation on acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods Seventy-eight patients with chronic obstructive pulmonary disease (COPD) were randomly divided into treatment group and control group. On the basis of routine treatment, the control group was given conventional drugs dexamethasone, α-chymotrypsin and gentamicin atomization; the treatment group was given pulmicort and mucosolvan combined with inhalation. Results After treatment, the symptoms of shortness of breath and dyspnea were improved in the treatment group over the control group, with significant difference between the two groups (P <0.05). Conclusions Pulmicort respules and mucosolvan combined with inhalation have the effect of relieving the symptoms and improving the symptoms quickly, and are of great significance in the treatment of acute exacerbation of chronic obstructive pulmonary disease.